Changes in Beneficial Ownership · 4
4D Molecular Therapeutics, Inc.
FDMTNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-08-19
- Issuer
- 4D Molecular Therapeutics, Inc.
- Issuer CIK
- 0001650648
- Trading symbol
- FDMT
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Kirn David
- Reporting owner CIK
- 0001834021
- Relationship
- Director · Officer
- Officer title
- See Remarks
- Address
- C/O 4D MOLECULAR THERAPEUTICS INC., 5858 HORTON STREET #455, EMERYVILLE, CA, 94608
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-19 | M · Form 4[F1] | 50,000 | A | 4.14 | 894,895 | D |
| Common Stock | 2026-08-19 | S · Form 4[F1] | 43,149 | D | 15.3566[F2] | 851,746 | D |
| Common Stock | 2026-08-19 | S · Form 4[F1] | 25,927 | D | 16.4173[F3] | 825,819 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 4.14 | 2026-08-19 | M · Form 4[F1] | 50,000 | D | 0 | [F4] | 2035-03-05 | Common Stock | 50,000 | 217,500 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.↩ 1↩ 2↩ 3↩ 4
- F2
- The transaction was executed in multiple trades in prices ranging from $14.91 to $15.84, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.↩ 1
- F3
- The transaction was executed in multiple trades in prices ranging from $15.97 to $16.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.↩ 1
- F4
- The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.↩ 1
Remarks
President and Chief Executive Officer
Signature 1
- Signed
- /s/ Scott Bizily as Attorney-in-Fact for David Kirn
- Date
- 2026-08-21